drugset / Trial / NCT05509816
A Study of Imlunestrant (LY3484356) in Healthy Women
NaCrossoverOpen-labelBasic science
Summary
The main purpose of this study is to evaluate the effect of imlunestrant (LY3484356) when administered orally on the levels of midazolam in the blood stream in healthy women of non-childbearing potential. The study will also evaluate the safety and tolerability of imlunestrant in healthy women of non-childbearing potential. This study will last up to approximately 6 weeks for each participant including the screening period.
Timeline
- Start
- 2022-09-12
- Primary completion
- 2022-11-30
- Completion
- 2022-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imlunestrant | Small molecule | 400 mg | Oral |
| Subject | Midazolam | Small molecule | 0.5 mg | Oral |
Indications
No indication recorded.